Key facts
- It has raised $31.0M.
- Notable investors include Khosla Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Liberate Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Liberate Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Liberate Bio
Developer of a genetic medicine technology designed to enable targeted delivery beyond the liver for broader therapeutic impact. The company offers a scalable system for extrahepatic delivery at industrial speed, enabling biotech researchers and pharmaceutical developers to unlock the potential of gene editing.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 12
- Website
- liberatebio.com/
- Ownership
- Privately Held (backing)
Liberate Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Liberate Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Liberate Bio in its N-PORT filings yet. We sweep new filings monthly.